

Freedom of Information request 194-22

Request

I am researching the incidence and treatment of CLL and MCL. I would greatly appreciate if you could answer the following questions.

Q1. How many patients has your trust treated in the past 3 months for the following conditions:

- Chronic Lymphocytic Leukaemia (CLL)
- Mantle Cell Lymphoma (MCL)
- In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

- BR (bendamustine + rituximab)
- Calquence (acalabrutinib)
- FCR (fludarabine + cyclophosphamide + rituximab)
- Gazyva (obinutuzumab) + chlorambucil
- Imbruvica (ibrutinib)
- Venclexta (venetoclax)
- Venclexta (venetoclax) + Gazyva (obinutuzumab)
- Venclexta (venetoclax) + rituximab
- Zydelig (idelalisib) + rituximab
- Any other systemic anti-cancer therapy

Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

- BR (bendamustine + rituximab)
- Imbruvica (ibrutinib)
- Imbruvica (ibrutinib) + rituximab
- R-BAC (rituximab, bendamustine and cytarabine)
- R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone)
- Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone)
- Velcade (bortezomib) + chemotherapy
- Any other systemic anti-cancer therapy
- Stem cell transplant
- Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells

Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

Response

1. The following number of patients have been treated in the past 3 months:
 - Chronic Lymphocytic Leukaemia (CLL) - 19
 - Mantle Cell Lymphoma (MCL) - <5
2. The following number of Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months:
 - BR (bendamustine + rituximab) - 0
 - Calquence (acalabrutinib) - 0
 - FCR (fludarabine + cyclophosphamide + rituximab) - 0
 - Gazyva (obinutuzumab) + chlorambucil - 0
 - Imbruvica (ibrutinib) - 16
 - Venclexta (venetoclax) - <5
 - Venclexta (venetoclax) + Gazyva (obinutuzumab) - 0
 - Venclexta (venetoclax) + rituximab - 0
 - Zydelig (idelalisib) + rituximab - 0
 - Any other systemic anti-cancer therapy - 0
3. The following number of Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months:
 - BR (bendamustine + rituximab) - 0
 - Imbruvica (ibrutinib) - <5
 - Imbruvica (ibrutinib) + rituximab - 0
 - R-BAC (rituximab, bendamustine and cytarabine) - 0
 - R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) - 0
 - Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone) - 0
 - Velcade (bortezomib) + chemotherapy - 0
 - Any other systemic anti-cancer therapy - <5
 - Stem cell transplant - 0
 - Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells – 0
4. Yes, NHS Borders is participating in ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL). Please see details below:
 - FLAIR: <5 patients.
 - ARCTIC: 6 patients recruited.
5. No, NHS Borders does not in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL).

As NHS Borders is such a small Board and the number of patients are very small, to provide further details could allow individuals to be identified and we would be in breach of the Data Protection Act 2018. We are therefore withholding all other data under Section 38(1)(b) of the Freedom of Information (Scotland) Act 2002. This is in accordance with the Code of Practice for Official Statistics which states that any number that is less than five; actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the ISD Statistical Disclosure Control Protocol.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **194-22** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.